MDxHealth SA
MDXH
查看詳細走勢圖
3.335USD
+0.185+5.87%
交易中 （美東）報價延遲15分鐘
165.07M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+5.87%
5天
+0.45%
1月
+0.45%
6月
+68.18%
今年開始到現在
+40.72%
1年
+47.57%
查看詳細走勢圖
TradingKey MDxHealth SA股票評分
單位: USD 更新時間: 2025-12-19操作建議
MDxHealth SA當前公司基本面數據相對穩定，增長潛力很大。當前估值低估，在生物技術與醫療研究行業排名99/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為強力買入。最高目標價7.04。中期看，股價處於下降通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
MDxHealth SA評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
6
分析師
強力買入
評級
6.040
目標均價
+325.35%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
MDxHealth SA亮點
亮點風險
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
業績高增長
公司營業收入穩步增長，連續3年增長143.02%
業績增長期
公司處於發展階段，最新年度總收入90.05M美元
估值合理
公司最新PE估值-3.16，處於3年歷史合理位
機構減倉
最新機構持股21.80M股，環比減少9.10%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉202.80K股
活躍度增加
近期活躍度增加，過去20天平均換手率0.58
MDxHealth SA新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
MDxHealth SA簡介
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
公司代碼MDXH
公司MDxHealth SA
CEOMr. Michael K. McGarrity
網址https://mdxhealth.com/
常見問題
MDxHealth SA(MDXH)的當前股價是多少？
MDxHealth SA(MDXH)的當前股價是 3.335。
MDxHealth SA 的股票代碼是什麼？
MDxHealth SA的股票代碼是MDXH。
MDxHealth SA股票的52週最高點是多少？
MDxHealth SA股票的52週最高點是--。
MDxHealth SA股票的52週最低點是多少？
MDxHealth SA股票的52週最低點是--。
MDxHealth SA的市值是多少？
MDxHealth SA的市值是165.07M。
MDxHealth SA的淨利潤是多少？
MDxHealth SA的淨利潤為-38.07M。
現在MDxHealth SA(MDXH)的股票是買入、持有還是賣出？
根據分析師評級，MDxHealth SA(MDXH)的總體評級為--，目標價格為6.040。
MDxHealth SA(MDXH)股票的每股收益（EPS TTM）是多少
MDxHealth SA(MDXH)股票的每股收益（EPS TTM）是-0.998。
相關品種
-0.24%
+0.42%
+0.69%
+0.20%
+0.65%
+2.90%
+1.20%
-0.27%
-0.14%
+0.28%
-0.52%
+0.15%
+0.79%
-0.28%
+0.08%
+0.66%
+1.73%
0.00%
+0.94%
+1.80%
